$14.7 Billion is the total value of Baker Brothers Advisors's 109 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 11.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Seattle Genetics, Inc. | $4,274,891,000 | +23.4% | 50,057,277 | 0.0% | 29.08% | +23.5% | |
| INCY | Buy | Incyte Corporation | $2,373,620,000 | -12.6% | 31,976,557 | +0.0% | 16.15% | -12.5% |
| ACAD | Buy | ACADIA Pharmaceuticals Inc. | $1,470,357,000 | +40.0% | 40,854,586 | +4.0% | 10.00% | +40.1% |
| BGNE | BeiGene, Ltd.sponsored adr | $1,442,246,000 | -1.2% | 11,777,285 | 0.0% | 9.81% | -1.1% | |
| ALXN | Alexion Pharmaceuticals, Inc. | $808,795,000 | -25.2% | 8,258,068 | 0.0% | 5.50% | -25.2% | |
| AMRN | Amarin Corporation plcsponsored adr | $629,811,000 | -21.8% | 41,544,288 | 0.0% | 4.28% | -21.7% | |
| GHDX | Sell | Genomic Health, Inc. | $626,973,000 | +16.4% | 9,244,665 | -0.2% | 4.26% | +16.5% |
| BMRN | BioMarin Pharmaceutical Inc. | $511,518,000 | -21.3% | 7,589,294 | 0.0% | 3.48% | -21.2% | |
| ASND | Ascendis Pharma A/Ssponsored adr | $326,551,000 | -16.4% | 3,390,270 | 0.0% | 2.22% | -16.3% | |
| NVTA | Buy | Invitae Corporation | $169,435,000 | +84.8% | 8,792,678 | +125.3% | 1.15% | +85.1% |
| KOD | Buy | Kodiak Sciences Inc. | $131,507,000 | +22.9% | 9,145,116 | +0.0% | 0.90% | +23.1% |
| NBIX | Neurocrine Biosciences, Inc. | $127,531,000 | +6.7% | 1,415,283 | 0.0% | 0.87% | +6.9% | |
| ARGX | argenx SEsponsored adr | $116,189,000 | -19.5% | 1,019,557 | 0.0% | 0.79% | -19.5% | |
| HRTX | Heron Therapeutics, Inc. | $111,335,000 | -0.5% | 6,018,104 | 0.0% | 0.76% | -0.4% | |
| MRTX | Sell | Mirati Therapeutics, Inc. | $101,846,000 | -60.7% | 1,307,220 | -48.0% | 0.69% | -60.6% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $100,815,000 | -17.7% | 1,169,278 | 0.0% | 0.69% | -17.6% | |
| MYOK | Buy | MyoKardia, Inc. | $79,124,000 | +55.3% | 1,517,237 | +49.3% | 0.54% | +55.5% |
| ONCE | Spark Therapeutics, Inc. | $72,922,000 | -5.3% | 751,927 | 0.0% | 0.50% | -5.2% | |
| TCDA | Tricida, Inc. | $60,811,000 | -21.8% | 1,969,905 | 0.0% | 0.41% | -21.6% | |
| RYTM | Rhythm Pharmaceuticals, Inc. | $58,470,000 | -1.9% | 2,708,200 | 0.0% | 0.40% | -1.7% | |
| IGMS | New | IGM Biosciences, Inc. | $55,806,000 | – | 3,144,000 | +100.0% | 0.38% | – |
| CERS | Cerus Corporation | $55,416,000 | -8.3% | 10,749,937 | 0.0% | 0.38% | -8.3% | |
| RARX | Buy | Ra Pharmaceuticals, Inc. | $55,471,000 | +2.4% | 2,345,496 | +30.2% | 0.38% | +2.4% |
| DBVT | DBV Technologies S.A.sponsored adr | $47,382,000 | +4.6% | 5,509,560 | 0.0% | 0.32% | +4.5% | |
| PRNB | Sell | Principia Biopharma Inc. | $46,710,000 | -21.3% | 1,654,029 | -7.5% | 0.32% | -21.1% |
| BCEL | Atreca, Inc. | $43,241,000 | -35.0% | 3,532,760 | 0.0% | 0.29% | -35.0% | |
| GWPH | GW Pharmaceuticals plcads | $42,658,000 | -33.3% | 370,845 | 0.0% | 0.29% | -33.2% | |
| ZYME | Zymeworks Inc. | $42,370,000 | +12.7% | 1,708,472 | 0.0% | 0.29% | +12.9% | |
| BOLD | Audentes Therapeutics, Inc. | $42,316,000 | -25.8% | 1,506,438 | 0.0% | 0.29% | -25.8% | |
| Neurocrine Biosciences, Inc.note 2.25% 5/15/2024 | $42,113,000 | +3.9% | 30,770,000 | 0.0% | 0.29% | +3.6% | ||
| INSM | Sell | Insmed Incorporated | $39,333,000 | -37.6% | 2,229,760 | -9.4% | 0.27% | -37.4% |
| BCRX | Sell | BioCryst Pharmaceuticals, Inc. | $36,458,000 | -33.1% | 12,725,472 | -11.5% | 0.25% | -33.0% |
| ADPT | Adaptive Biotechnologies Corporation | $36,011,000 | -36.0% | 1,165,411 | 0.0% | 0.24% | -36.0% | |
| KRYS | Krystal Biotech, Inc. | $35,929,000 | -13.8% | 1,034,674 | 0.0% | 0.24% | -13.8% | |
| NLTX | New | Neoleukin Therapeutics, Inc. | $32,221,000 | – | 11,305,679 | +100.0% | 0.22% | – |
| CBAY | CymaBay Therapeutics, Inc. | $29,222,000 | -28.5% | 5,707,411 | 0.0% | 0.20% | -28.4% | |
| ALLK | New | Allakos Inc. | $26,710,000 | – | 339,690 | +100.0% | 0.18% | – |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $23,824,000 | -37.1% | 2,799,577 | 0.0% | 0.16% | -37.2% | |
| MRUS | Merus N.V. | $20,671,000 | +21.6% | 1,160,014 | 0.0% | 0.14% | +22.6% | |
| QURE | uniQure N.V. | $20,377,000 | -49.6% | 517,700 | 0.0% | 0.14% | -49.5% | |
| URGN | New | UroGen Pharma Ltd. | $17,819,000 | – | 747,751 | +100.0% | 0.12% | – |
| AXSM | Axsome Therapeutics, Inc. | $15,631,000 | -21.4% | 772,286 | 0.0% | 0.11% | -21.5% | |
| BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 | $14,722,000 | -5.4% | 15,000,000 | 0.0% | 0.10% | -5.7% | ||
| XNCR | Xencor, Inc. | $14,440,000 | -17.6% | 428,120 | 0.0% | 0.10% | -17.6% | |
| AIMT | Aimmune Therapeutics, Inc. | $14,112,000 | +0.6% | 673,908 | 0.0% | 0.10% | +1.1% | |
| PTGX | Buy | Protagonist Therapeutics, Inc. | $14,103,000 | +17.0% | 1,174,282 | +18.0% | 0.10% | +17.1% |
| LJPC | La Jolla Pharmaceutical Company | $13,721,000 | -4.9% | 1,559,231 | 0.0% | 0.09% | -5.1% | |
| IDRA | Buy | Idera Pharmaceuticals, Inc. | $13,319,000 | +8.3% | 4,608,786 | +0.1% | 0.09% | +8.3% |
| AGLE | Aeglea BioTherapeutics, Inc. | $13,178,000 | +12.3% | 1,713,604 | 0.0% | 0.09% | +12.5% | |
| ALKS | Buy | Alkermes plc | $12,194,000 | +35.2% | 625,030 | +56.3% | 0.08% | +36.1% |
| SYRS | Syros Pharmaceuticals, Inc. | $10,119,000 | +12.1% | 974,835 | 0.0% | 0.07% | +13.1% | |
| SGMO | Sangamo Therapeutics, Inc. | $9,048,000 | -16.0% | 999,823 | 0.0% | 0.06% | -15.1% | |
| ASMB | Assembly Biosciences, Inc. | $7,896,000 | -27.1% | 803,246 | 0.0% | 0.05% | -27.0% | |
| MRKR | Marker Therapeutics, Inc. | $7,665,000 | -35.5% | 1,500,000 | 0.0% | 0.05% | -35.8% | |
| APLS | Apellis Pharmaceuticals, Inc. | $7,558,000 | -4.9% | 313,725 | 0.0% | 0.05% | -5.6% | |
| CPRX | Sell | Catalyst Pharmaceuticals, Inc. | $7,125,000 | -27.5% | 1,341,902 | -47.6% | 0.05% | -28.4% |
| HOOK | HOOKIPA Pharma Inc. | $6,696,000 | +11.4% | 892,857 | 0.0% | 0.05% | +12.2% | |
| ACOR | Buy | Acorda Therapeutics, Inc. | $6,408,000 | -58.5% | 2,232,589 | +11.0% | 0.04% | -58.1% |
| DERM | Dermira, Inc. | $5,795,000 | -33.2% | 906,943 | 0.0% | 0.04% | -33.9% | |
| XBIT | Buy | Xbiotech Inc. | $5,453,000 | +89.1% | 521,327 | +37.0% | 0.04% | +85.0% |
| ARAV | Buy | Aravive, Inc. | $4,981,000 | +71.2% | 664,088 | +36.9% | 0.03% | +70.0% |
| MIST | Milestone Pharmaceuticals Inc. | $4,973,000 | -31.3% | 266,667 | 0.0% | 0.03% | -30.6% | |
| ALBO | Albireo Pharma, Inc. | $5,000,000 | -38.0% | 250,000 | 0.0% | 0.03% | -38.2% | |
| ORTX | Orchard Therapeutics plcads | $4,820,000 | -15.1% | 405,702 | 0.0% | 0.03% | -15.4% | |
| HALO | Halozyme Therapeutics, Inc. | $4,653,000 | -9.7% | 299,969 | 0.0% | 0.03% | -8.6% | |
| NXTC | NextCure, Inc. | $4,628,000 | +106.0% | 150,000 | 0.0% | 0.03% | +106.7% | |
| IFRX | New | Inflarx N.V. | $4,393,000 | – | 1,778,415 | +100.0% | 0.03% | – |
| ANAB | AnaptysBio, Inc. | $3,957,000 | -38.0% | 113,086 | 0.0% | 0.03% | -37.2% | |
| ACHN | Achillion Pharmaceuticals, Inc. | $3,943,000 | +34.3% | 1,095,359 | 0.0% | 0.03% | +35.0% | |
| GLPG | Galapagos NVsponsored adr | $3,827,000 | +18.4% | 25,072 | 0.0% | 0.03% | +18.2% | |
| BLUE | bluebird bio, Inc. | $3,673,000 | -27.8% | 40,000 | 0.0% | 0.02% | -28.6% | |
| NGM | NGM Biopharmaceuticals, Inc. | $3,463,000 | -5.4% | 250,000 | 0.0% | 0.02% | -4.0% | |
| MIRM | New | Mirum Pharmaceuticals, Inc. | $3,353,000 | – | 333,333 | +100.0% | 0.02% | – |
| XLRN | Acceleron Pharma Inc. | $3,315,000 | -3.8% | 83,900 | 0.0% | 0.02% | 0.0% | |
| MNLO | Menlo Therapeutics Inc. | $3,136,000 | -25.2% | 700,000 | 0.0% | 0.02% | -25.0% | |
| GTHX | G1 Therapeutics, Inc. | $2,898,000 | -25.7% | 127,236 | 0.0% | 0.02% | -25.9% | |
| HARP | Harpoon Therapeutics, Inc. | $2,927,000 | +5.1% | 214,285 | 0.0% | 0.02% | +5.3% | |
| VKTX | Viking Therapeutics, Inc. | $2,924,000 | -17.1% | 425,000 | 0.0% | 0.02% | -16.7% | |
| ABEO | Abeona Therapeutics Inc. | $2,911,000 | -52.7% | 1,288,235 | 0.0% | 0.02% | -52.4% | |
| BLCM | Bellicum Pharmaceuticals, Inc. | $2,812,000 | -38.2% | 2,677,818 | 0.0% | 0.02% | -38.7% | |
| DOVA | Buy | Dova Pharmaceuticals, Inc. | $2,857,000 | +103.8% | 102,205 | +2.8% | 0.02% | +90.0% |
| YMAB | Y-mAbs Therapeutics, Inc. | $2,679,000 | +14.0% | 102,800 | 0.0% | 0.02% | +12.5% | |
| CRNX | Buy | Crinetics Pharmaceuticals, Inc. | $2,632,000 | -20.8% | 175,000 | +31.6% | 0.02% | -21.7% |
| CYCN | Cyclerion Therapeutics, Inc. | $2,455,000 | +5.8% | 202,581 | 0.0% | 0.02% | +6.2% | |
| SBPH | Spring Bank Pharmaceuticals, Inc. | $2,109,000 | -6.8% | 613,144 | 0.0% | 0.01% | -6.7% | |
| AUTL | Autolus Therapeutics plcspon ads | $1,947,000 | -22.9% | 156,773 | 0.0% | 0.01% | -23.5% | |
| NTLA | Intellia Therapeutics, Inc. | $1,716,000 | -18.4% | 128,538 | 0.0% | 0.01% | -14.3% | |
| IDYA | IDEAYA Biosciences, Inc. | $1,800,000 | -9.6% | 200,000 | 0.0% | 0.01% | -14.3% | |
| MTEM | Molecular Templates, Inc. | $1,675,000 | -21.1% | 254,230 | 0.0% | 0.01% | -21.4% | |
| FTSV | Forty Seven, Inc. | $1,605,000 | -39.4% | 250,000 | 0.0% | 0.01% | -38.9% | |
| CTMX | CytomX Therapeutics, Inc. | $1,435,000 | -34.2% | 194,377 | 0.0% | 0.01% | -33.3% | |
| CCXI | ChemoCentryx, Inc. | $1,404,000 | -27.1% | 207,029 | 0.0% | 0.01% | -23.1% | |
| FOMX | Foamix Pharmaceuticals Ltd. | $1,514,000 | +27.7% | 498,189 | 0.0% | 0.01% | +25.0% | |
| FLGT | Fulgent Genetics, Inc. | $1,299,000 | +55.6% | 125,000 | 0.0% | 0.01% | +50.0% | |
| MTNB | New | Matinas BioPharma Holdings, Inc. | $1,252,000 | – | 1,984,965 | +100.0% | 0.01% | – |
| LPTX | New | Leap Therapeutics, Inc. | $1,145,000 | – | 978,454 | +100.0% | 0.01% | – |
| RCUS | Arcus Biosciences, Inc. | $1,106,000 | +14.5% | 121,534 | 0.0% | 0.01% | +14.3% | |
| GLMD | Galmed Pharmaceuticals Ltd. | $1,031,000 | -35.0% | 215,594 | 0.0% | 0.01% | -36.4% | |
| ADMS | Adamas Pharmaceuticals, Inc. | $883,000 | -17.5% | 172,630 | 0.0% | 0.01% | -14.3% | |
| CNST | Constellation Pharmaceuticals, Inc. | $861,000 | -47.4% | 133,333 | 0.0% | 0.01% | -45.5% | |
| SRRA | Sierra Oncology, Inc. | $781,000 | -30.3% | 2,000,000 | 0.0% | 0.01% | -37.5% | |
| INFI | Infinity Pharmaceuticals, Inc. | $598,000 | -42.8% | 580,400 | 0.0% | 0.00% | -42.9% | |
| AFMD | Affimed N.V. | $588,000 | +2.4% | 200,000 | 0.0% | 0.00% | 0.0% | |
| SNSS | Sunesis Pharmaceuticals, Inc. | $401,000 | -1.0% | 556,665 | 0.0% | 0.00% | 0.0% | |
| EVFM | New | Evofem Biosciences, Inc. | $514,000 | – | 102,048 | +100.0% | 0.00% | – |
| DVAX | Dynavax Technologies Corporation | $268,000 | -10.4% | 75,000 | 0.0% | 0.00% | 0.0% | |
| AQST | Aquestive Therapeutics, Inc. | $317,000 | -24.2% | 99,600 | 0.0% | 0.00% | -33.3% | |
| RTTR | Ritter Pharmaceuticals, Inc. | $87,000 | -71.0% | 279,999 | 0.0% | 0.00% | -50.0% | |
| Trillium Therapeutics Inc. | $155,000 | -6.6% | 505,262 | 0.0% | 0.00% | 0.0% | ||
| ALRN | Exit | Aileron Therapeutics, Inc. | $0 | – | -2,040,000 | -100.0% | -0.01% | – |
| AQXP | Exit | Aquinox Pharmaceuticals, Inc. | $0 | – | -10,934,154 | -100.0% | -0.18% | – |
| ARRY | Exit | Array BioPharma Inc. | $0 | – | -2,848,567 | -100.0% | -0.90% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.